giichinese.com logo
giichinese.com logo
日商環球訊息有限公司


垂直整合市場
- Japanese Korean English
Report
[英文調查報告書]

全球生命科學取向中間體企業:DowPharma

The Top 10 World's Leading Life Science Intermediate Companies: DowPharma

商品編碼 : 57822
出版日期 : 2006/06

Price

-
此出版品為英文撰寫

Abstract

A concise market analysis, including:

  • Major U.S. and international trends with potentially significant impact on the life science intermediates industry during the next five years, including industry consolidation, market globalization, environmental regulations, etc.
  • Analysis of major market segments.
  • Review of key geographic regions, including North America, Europe, Asia, Latin America and others.
  • Five-year worldwide market forecasts for:
    • Major market segments.
    • Key geographic regions.

Table of Contents

SECTION I. EXECUTIVE SUMMARY

  • A 3-5 page synopsis of main sections.

SECTION II. BUSINESS ORGANIZATION

  • History of the life science intermediates business evolution, important to the understanding of the corporate culture, management mentality and strategies.
  • Recent acquisitions, divestitures and significant organizational changes.
  • Current organizational structure.

SECTION III. SENIOR MANAGEMENT

  • Background of key executives.

SECTION IV. FACILITIES AND EMPLOYEES

  • Major administrative, manufacturing and R&D facilities in the U.S. and abroad.
  • New plants under construction.
  • U.S. and international work force size and distribution.

SECTION V.TECHNOLOGICAL KNOW-HOW

  • Internally developed and acquired technologies, and related capabilities.
  • Proprietary technologies and patent litigations.

SECTION VI. PRODUCT PORTFOLIO

  • Extensive review of major product lines.

SECTION VII. MARKETING TACTICS

  • Major promotional strategies.
  • Distribution approaches.
  • Product service and support.

SECTION VIII. FINANCIAL ANALYSIS

  • Sales and operating profit by division, product line, geographic region and country.
  • Five-year sales and profit performance.

SECTION IX. R&D EXPENDITURES AND MAJOR PROGRAMS

  • Estimated R&D budget.
  • Research facilities and staff.
  • New technologies, products and applications in development.

SECTION X. COLLABORATIVE ARRANGEMENTS

  • Major joint venture, distribution, OEM and licensing partners, both industrial and academic.
  • Terms of collaborative agreements and specific products involved.

SECTION XI. STRATEGIC DIRECTION

  • Specific business, new product development and marketing strategies.
  • Strengths and weaknesses.
  • Anticipated acquisitions, joint ventures and divestitures.
-
此出版品為英文撰寫

Top

[英文調查報告書]
全球生命科學取向中間體企業:DowPharma
The Top 10 World's Leading Life Science Intermediate Companies: DowPharma

出版商 : Venture Planning Group Venture Planning Group
代理商 : Global Information, Inc. Global Information, Inc.

US $ 1,250 (Hard Copy)
US $ 1,500 (PDF by E-mail (Site License))
商品編碼 : 57822

本頁所標示之售價為不含購買者所在地消費稅之未稅價格,相關消費稅金將另行加至交易金額中